Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
12 Aug, 20:00
NYSE NYSE
$
260. 86
+1.06
+0.408%
$
620.77B Market Cap
29.06 P/E Ratio
0.69% Div Yield
3.26M Volume
9.91 Eps
$ 259.8
Previous Close
Add Transaction
Day Range
255.25 261.41
Year Range
171.81 274.9
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors

Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors

In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.

Zacks | 1 year ago
US FDA declines to approve injection form of J&J's lung cancer drug

US FDA declines to approve injection form of J&J's lung cancer drug

The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for a type of lung cancer, the drugmaker said on Monday.

Reuters | 1 year ago
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
Johnson & Johnson Just Paid Investors: Here's How Much They Received

Johnson & Johnson Just Paid Investors: Here's How Much They Received

Johnson & Johnson (NYSE: JNJ) is rewarding its shareholders once again with a quarterly dividend of $1.24, payable on Tuesday, Dec.

247wallst | 1 year ago
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

In the most recent trading session, Johnson & Johnson (JNJ) closed at $150.47, indicating a -1.24% shift from the previous trading day.

Zacks | 1 year ago
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids

J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids

Johnson & Johnson JNJ announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients.

Zacks | 1 year ago
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding

How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding

Johnson & Johnson offers investors an effective combination of dividend income and dividend growth, evidenced by its Dividend Yield [TTM] of 3.13% and 5-Year Dividend Growth Rate [CAGR] of 5.61%. The company from the Pharmaceuticals Industry, which has an Aaa credit rating from Moody's, can serve as a strategically important core-position within your dividend portfolio. Allocating the largest proportion of your dividend portfolio to Johnson & Johnson can position your portfolio for reduced volatility and help to decrease its overall risk level.

Seekingalpha | 1 year ago
2 Very Healthy Dividend Stocks to Hold for Decades of Income

2 Very Healthy Dividend Stocks to Hold for Decades of Income

Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.

Fool | 1 year ago
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC

J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC

If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.

Zacks | 1 year ago
2 Unstoppable Dividend Stocks to Buy Now With $500

2 Unstoppable Dividend Stocks to Buy Now With $500

2 Unstoppable Dividend Stocks to Buy Now With $500

Fool | 1 year ago
3 Dividend Kings So You Can Sleep Well At Night

3 Dividend Kings So You Can Sleep Well At Night

Dividend Kings, like Coca-Cola, Johnson & Johnson, and Walmart, are prime long-term investments due to their consistent dividend growth over 50+ years. Coca-Cola offers a 3% yield and strong EBITDA growth, making it a solid buy despite recent stock volatility and health-related headwinds. Johnson & Johnson, despite legal issues, remains undervalued with a 3.2% yield and robust free cash flow, making it an attractive investment.

Seekingalpha | 1 year ago
Loading...
Load More